DHR — Danaher Corporation

Danaher Corporation (DHR) is a diagnostics & research company listed on NYSE. It is led by Rainer M. Blair, based in 2200 Pennsylvania Avenue N.W., Washington, DC, United States, 20037-1701, with about 61,000 employees. Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a partnership with AstraZeneca PLC to develop and commercialize diagnostic tools and tests. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and

Latest reported DHR revenue for 2026-03-27 was $5.95B. Net income was $1.03B. Revenue was down 75.8% from 2025-12-31 to 2026-03-27. DHR currently screens at market cap $144.18B and trailing P/E 39.0.

Use this DHR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DHR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DHR SEC filings page. Lician reads the product cache first so this HTML stays unique to Danaher Corporation even when a live quote feed is slow.